Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Somalogic; Athlomics; NuGen Technologies; Epitomics; BioArray Solutions; Brandeis University; Illumina; Agilent Technologies

Premium

Somalogic of Boulder, Colo., has received US Patent No. 8,071,288, "Methods and reagents for detecting target binding by nucleic acid ligands." Using universal protein stains, proteins bound by nucleic acid ligands may be labeled with a detectable moiety. The methods and reagents are particularly useful for the detection of protein targets bound to multiplexed arrays of nucleic acid ligands. The patent also provides methods for the multiplexed evaluation of photocrosslinking nucleic acid ligands. The methods allow one simultaneously to evaluate the performance of photocrosslinking nucleic acid ligands and to assess the specificity of each photocrosslinking nucleic acid ligand for its cognate target protein. Photocrosslinking nucleic acid ligands with the most desirable properties can then be selected for use in diagnostic and prognostic medical assays.


Athlomics of Toowong, Australia, has received US Patent No. 8,071,305, "Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection." The method relies on gene expression arrays to diagnose and assess animals with herpes virus infection, and determine those animals at risk of developing a herpes virus infection or its sequelae. The inventors claim the approach has use in the early diagnosis of disease, in monitoring an animal's immune response to the disease, and in enabling better treatment and management decisions to be made in clinically and sub-clinically affected animals.


NuGen Technologies of San Carlos, Calif., has received US Patent No. 8,071,311, "Methods and compositions for amplification of RNA sequences." The methods rely on a composite primer, a second primer, and strand displacement to generate multiple copies of DNA products comprising sequences complementary to an RNA sequence of interest. The methods also employ a single primer and strand displacement to generate multiple copies of DNA products comprising sequences complementary to an RNA sequence of interest. According to the patent, the methods are useful for preparation of nucleic acid libraries and substrates for analysis of gene expression of cells in biological samples.


Epitomics of Burlingame, Calif., has received US Patent No. 8,071,322, "Method for identifying differentially expressed proteins." The method involves generating a first and second labeled population of antibodies that react to two samples; contacting the first and second labeled populations of antibodies with antigens; and identifying any resultant antigens that are differentially bound by the first and second populations of antibodies. The antigens may be on the surface of cells, or on a solid support. Once identified, the nucleic acid encoding an antigen of interest may be identified and sequenced to reveal the identity of the antigen of interest.


BioArray Solutions of Warren, NJ, (now part of Immucor) has received US Patent No. 8,071,393, "Method of analyzing nucleic acids using an array of encoded beads." The patent claims a method for manipulating colloidal particulates and biomolecules at the interface between an insulating electrode such as silicon oxide and an electrolyte solution. Light-controlled electrokinetic assembly of particles near surfaces relies on the combination of three functional elements: the AC electric field-induced assembly of planar aggregates; the patterning of the electrolyte/silicon oxide/silicon interface to exert spatial control over the assembly process; and the real-time control of the assembly process via external illumination. The methods enable interactive control over the creation and placement of planar arrays of several types of particles and biomolecules and the manipulation of array shape and size, according to the inventors.


Brandeis University of Waltham, Mass., has received US Patent No. 8,071,734, "Nucleic acid-based detection." A method for simultaneously detecting the presence and quantity of different compounds in a sample using aptamer beacons is claimed. According to the patent, aptamer beacons are oligonucleotides that have a binding region that can bind to a non-nucleotide target molecule, such as a protein, a steroid, or an inorganic molecule. New aptamer beacons having binding regions configured to bind to different target molecules can be used in solution-based and solid, array-based systems. The aptamer beacons described in the patent can be attached to solid supports, such as at different predetermined points in two-dimensional arrays.


Illumina of San Diego has received US Patent No. 8,071,962, "Compensator for multiple surface imaging." A method for imaging biological samples on multiple surfaces of a support structure is claimed, where the support may be a flow cell through which a reagent fluid is allowed to flow and interact with biological samples. Excitation radiation from a radiation source may be used to excite the biological samples on multiple surfaces. In this manner, fluorescent emission radiation may be generated from the biological samples and subsequently captured and detected and used to generate image data.


Agilent Technologies has received US Patent No. 8,073,626, "Biopolymer array reading." The method relies on reading a different array identifier for each biopolymer array from a tag associated with that array. The results from each read array are saved in a memory linked with the read identifier for that array. The saved results for each array are matched with one of the different communication addresses using the identifier, and the saved results transmitted for those arrays to the matched different communication addresses.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more